BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease – Results of the German Hodgkin Study Group

References

• Carde P, Noordijk E, Hagenbeek A, Kluin-Nelemans J C, Thomas J, Tirelli U, et al. Superiority of EBVP chemotherapy in combination with involved field irradiation over subtotal nodal irradiation in favorable clinical stage I-II Hodgkin's disease: The EORTC-GPMC H7F randomized trial. Proc Amer Soc Clin Oncol 1997; 16: 13, (abstr.)
   Google Scholar
• Tesch H, Sieber M, Rueffer U, Bnilant C, Reinke T, Hermann R, et al. Second interim analysis of the HD7 trial of the GHSG: 2 cycles ABVD plus extended field radio-therapy is more effective than radiotherapy alone in early stage HD. Blood 1999; 94: 2113, (abstr.)
   Web of Science ®Google Scholar
• Roach M, 3rd, Brophy N, Cox R, Varghese A, Hoppe R T. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 1990; 8: 623–629
   PubMed Web of Science ®Google Scholar
• Specht L, Horwich A, Ashley S. Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease. Int J Radiat Oncol Biol Phys 1994; 30: 805–811
   PubMed Web of Science ®Google Scholar
• Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 1997; 33: 848–853
   PubMed Web of Science ®Google Scholar
• Healey E A, Tarbell N J, Kalish L A, Silver B, Rosenthal D S, Marcus K, et al. Prognostic factors for patients with Hodgkin's disease in first relapse. Cancer 1993; 71: 2613–2620
   PubMed Web of Science ®Google Scholar
• Hoppe R T. The management of Hodgkin's disease in relapse after primary radiation therapy. Eur J Cancer 1992; 28: 1920–1922
   Web of Science ®Google Scholar
• Cadman E, Bloom A F, Prosnitz L, Farber L, Vera R, Bertino J, et al. The effective use of combined modality therapy for the treatment of patients with Hodgkin's disease who relapsed following radiotherapy. Am J Clin Oncol 1983; 6: 313–318
   PubMed Web of Science ®Google Scholar
• Vinciguerra V, Propert K J, Coleman M, Anderson J R, Stutzman L, Pajak T F, et al. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group. B J Clin Oncol 1986; 4: 838–846
   PubMed Web of Science ®Google Scholar
• Olver I N, Wolf M M, Cruickshank D, Worotniuk V, Ding J C, Cooper I A, Matthews J P. Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease. An analysis of long-term follow-up. Cancer 1988; 62: 233–239
   Google Scholar
• Santoro A, Viviani S, Villarreal C J, Bonfante V, Delfino A, Valagussa P, Bonadonna G. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986; 70: 343–348
   PubMedGoogle Scholar
• Abrahamsen A F, Hannisdal E, Nome O, Elgio R F, Holte H, Hager B, et al. Prognostic variables and results of salvage treatment in Hodgkin's disease. Acta Oncol 1996; 35(suppl 8)67–72
   PubMed Web of Science ®Google Scholar
• Cooper M R, Pajak T F, Gottlieb A J, Glicksman A S, Nissen N, Richards F, 2nd, et al. The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease. J Clin Oncol 1984; 2: 748–755
   PubMed Web of Science ®Google Scholar
• Canellos G P, Anderson J R, Propert K J, Nissen N, Cooper H R, Henderson E S, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1483
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457–481
   Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• Hartsell W F, Sarin P, Recine D C, Kazlauskas L I, Galinsky D L, Griern K L. Long-term results of curative irradiation in pathologically staged IA and IIA Hodgkin's disease. Radiology 1993; 186: 565–568
   PubMed Web of Science ®Google Scholar
• Zijlstra J M, Dressel A J, Mens J W, Tinteren H, Slotman B J, Jonkhoff A R, Huijgens P C. Radiation therapy in early stage Hodgkin's disease: long-term results and adverse effects. Hematol J 2002; 3: 179–184
   PubMedGoogle Scholar
• Zinzani P L, Barbieri E, Gherlinzoni F, Frezza G, Mazza P, Pica A, et al. Radiotherapy in early stage Hodgkin's disease. Leuk Lymphoma 1994; 13: 285–289
   PubMed Web of Science ®Google Scholar
• Maurizi Enrici R, Falchetto Osti M, Zurlo A, Anselmo A P, Iacari V, Mandelli F. Long-term results of 60 patients with pathologic stage I & IIA Hodgkin's disease treated with exclusive mantle radiation therapy. Eur J Haematol 1999; 63: 126–133
   PubMed Web of Science ®Google Scholar
• Noordijk E M, Carde P, Mandard A M, Mellink W A, Monconduit M, Eghbali H, et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. Ann Oncol 1994; 5(suppl 2)107–112
   PubMedGoogle Scholar
• Zapatero A, Lopez M A, Cerezo L, De Vidales C M, MarIn A, Perez-Torrubia A. Stage I-III Hodgkin's disease: outcome and pattern of failure following treatment with radiation therapy and chemotherapy in a modern era. Hematology 2002; 7: 43–50
   PubMedGoogle Scholar
• Amini R M, Glimelius B, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, Enblad G. A population-based study of the outcome for patients with first relapse of Hodgkin's lymphoma. Eur J Haematol 2002; 68: 225–232
   PubMed Web of Science ®Google Scholar
• Wirth A, Chao M, Corry J, Laidlaw C, Yuen K, Ryan G, et al. Mantle irradiation alone for clinical stage I-II Hodgkin's disease: long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 1999; 17: 230–240
   PubMed Web of Science ®Google Scholar
• Canellos G P, Young R C, DeVita V D. Combination therapy for advanced Hodgkin's disease in relapse following extensive radiotherapy. Clin Pharm Ther 1972; 13: 750–754
   PubMed Web of Science ®Google Scholar
• Portlock C S, Rosenberg S A, Glatsetin E, Kaplan H S. Impact of salvage treatment on initial relapses in patients with Hodgkin's disease, stages I-II. Blood 1978; 51: 825–833
   PubMed Web of Science ®Google Scholar
• DeVita V T, Jr, Simon R M, Hubbard S M, Young R C, Berard C W, Moxley J H, 3rd, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587–595
   PubMed Web of Science ®Google Scholar
• Peschel R E, Hou-Wun Mai D, Dowling S, Knowlton A, Farber L, Fischer J J. Pathologic stage I and II Hodgkin's disease. Long-term results at three Connecticut hospitals. Conn Med 1991; 55: 449–452
   PubMedGoogle Scholar